Interleukin-6 role in the severity of COVID-19 and intensive care unit stay length

Ruqaya Muhammed Ghareeb Taher Al Barzin1, Shler Ghafour Raheem1, Pinar Khalid Khudhur1

  • 1Microbiology Unit, Department of Basic Science, College of Medicine, Hawler Medical University, Erbil, Kurdistan Region-Iraq.

Insights

Elevated interleukin-6 (IL-6) levels in COVID-19 patients correlate with increased disease severity and longer intensive care unit (ICU) stays. This highlights IL-6 as a potential biomarker for critical illness progression in COVID-19.

Area of Science:

  • Immunology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • COVID-19 pathogenesis involves a 'cytokine storm,' with Interleukin-6 (IL-6) exacerbating immune responses.
  • Understanding IL-6 dynamics is crucial for evaluating disease severity and patient outcomes.

Purpose of the Study:

  • To investigate the association between Interleukin-6 (IL-6) levels and COVID-19 disease severity.
  • To explore the relationship between IL-6, nutritional status, and intensive care unit (ICU) admission.

Main Methods:

  • A cross-sectional study of 48 laboratory-confirmed COVID-19 patients.
  • IL-6 levels measured using electrochemiluminescence immunoassay (ECLIA).
  • Nutritional status assessed via Subjective Global Assessment (SGA) and calorie intake calculations.

Main Results:

  • ICU-admitted patients exhibited significantly higher IL-6 levels compared to ward patients (p=0.001).
  • Patients hospitalized for over 7 days showed markedly elevated IL-6 levels (119.2±28.3 pg/ml) versus those hospitalized for less than 7 days (89.04±34.1 pg/ml).
  • No significant differences in nutritional status or albumin levels were found between ICU and ward patients.

Conclusions:

  • IL-6 levels are associated with COVID-19 disease severity and duration of ICU stay.
  • Elevated IL-6 may serve as a biomarker for predicting critical illness and prolonged hospitalization in COVID-19 patients.
  • Nutritional status did not significantly correlate with ICU admission in this cohort.

Related Concept Videos

COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.6K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
2.1K
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.8K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
670
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
3.9K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
840